AIDX
20/20 Biolabs, Inc. Common Stock
NASDAQ: AIDX · HEALTHCARE · MEDICAL DEVICES
$1.40
-7.75% today
Updated 2026-06-05
Market cap
$6.97M
P/E ratio
—
P/S ratio
3.78x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$1 – $50
Volume
1.0M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F6.3
Quality
B2.0
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →204 stocks currently score above 75
Price targets
Analyst target
$5.00
+257.14%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.24x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at -279.10%
- Negative free cash flow $-1.29M
- Revenue declining -36.20% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $11.06M | $1.42M | $1.75M | $2.05M | $1.84M |
| Net income | $2.19M | $-6.39M | $-5.55M | $-3.74M | $-2.12M |
| EPS | — | — | — | — | $-0.49 |
| Free cash flow | $5.54M | $-4.64M | $-2.60M | $-1.92B | $-1.29M |
| Profit margin | 19.77% | -448.73% | -316.81% | -182.82% | -279.10% |
Peer comparison
Smart narrative
20/20 Biolabs, Inc. Common Stock trades at $1.40. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. TTM revenue stands at $1.84M. with profit margins at -279.10%.
Frequently asked questions
What is 20/20 Biolabs, Inc. Common Stock's stock price?
20/20 Biolabs, Inc. Common Stock (AIDX) trades at $1.40, on a P/S of 3.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is 20/20 Biolabs, Inc. Common Stock overvalued?
20/20 Biolabs, Inc. Common Stock carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of 20/20 Biolabs, Inc. Common Stock (AIDX)?
The 12-month analyst consensus target is $5.00, about 257.1% above the current $1.40. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is 20/20 Biolabs, Inc. Common Stock's revenue?
20/20 Biolabs, Inc. Common Stock's trailing twelve-month revenue is $1.84M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.78x
ROE-354.60%
Beta-0.43
50D MA$1.28
200D MA$2.34
Shares out0.01B
Float0.01B
Short ratio—
Avg volume1.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—